Cardiovascular changes associated with intravenous administration of fumonisin B1 in horses.
Abstract: To determine whether cardiovascular dysfunction is evident in horses with leukoencephalomalacia experimentally induced by administration of fumonisin B1. Methods: 11 healthy horses of various breeds (body weight, 252 to 367 kg). Methods: Horses were randomly assigned to 3 groups and administered fumonisin B1 daily. Horses received IV injections of 0 (control horses; n = 4), 0.01 (3), or 0.20 mg (4) of fumonisin B1/kg for 7 to 28 days. Horses were examined daily for evidence of neurologic disease. When neurologic signs consistent with leukoencephalomalacia were evident, horses were anesthetized, and catheters were inserted for evaluation of the cardiovascular system. After recovery from anesthesia, hemodynamic measurements were obtained. Results: Fumonisin-treated horses with clinical signs of neurologic disease had evidence of cardiovascular dysfunction manifested as decreases in heart rate, cardiac output, right ventricular contractility (assessed by measuring the maximal rate of change of right ventricular pressure), coccygeal artery pulse pressure, and pH and base excess in venous blood as well as increases in systemic vascular resistance, compared with values for control horses. Fumonisin-treated horses with and without clinical signs of neurologic disease also had higher serum and right ventricular sphinganine and sphingosine concentrations than control horses. Conclusions: An association was detected among fumonisin-induced neurologic disease, increased serum and myocardial sphinganine and sphingosine concentrations, and decreased cardiovascular function in horses. Fumonisin-induced decreases in cardiovascular function may contribute to the pathophysiologic development of leukoencephalomalacia in horses.
Publication Date: 2002-04-10 PubMed ID: 11939316DOI: 10.2460/ajvr.2002.63.538Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
- Journal Article
- Research Support
- U.S. Gov't
- Non-P.H.S.
Summary
This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.
The research investigates the impact of a toxin, fumonisin B1, on horses’ cardiovascular system and its potential contribution to a brain disease in horses known as leukoencephalomalacia.
Objective & Method of the Study
- The study aimed to discover if there is a link between cardiovascular dysfunction and leukoencephalomalacia in horses, which is experimentally induced by the administration of fumonisin B1.
- The study involved 11 healthy horses of different breeds. These horses were split into three groups and were given fumonisin B1 daily.
- The horses received 0, 0.01, or 0.20 mg of fumonisin B1/kg per day for a period ranging from 7 to 28 days.
- Each horse was observed daily for signs of neurological disease. Once signs were evident, the horses were anesthetized and catheters were inserted to inspect the cardiovascular system. Hemodynamic measurements were recorded after recovery from anesthesia.
Results
- Fumonisin-treated horses displaying signs of neurologic disease showed decreased heart rate, cardiac output, right ventricular contractility, coccygeal artery pulse pressure, and venous blood pH and base excess. These horses also showed increased systemic vascular resistance.
- Both the horses with and without symptoms of neurological disease demonstrated higher serum and right ventricular sphinganine and sphingosine concentrations than control horses.
Conclusion
- The study found a connection between fumonisin-induced neurologic disease, increased serum and myocardial sphinganine and sphingosine levels, and decreased cardiovascular function in horses.
- This suggests that the reduction in cardiovascular function induced by fumonisin may contribute to the development of leukoencephalomalacia in horses.
Cite This Article
APA
Smith GW, Constable PD, Foreman JH, Eppley RM, Waggoner AL, Tumbleson ME, Haschek WM.
(2002).
Cardiovascular changes associated with intravenous administration of fumonisin B1 in horses.
Am J Vet Res, 63(4), 538-545.
https://doi.org/10.2460/ajvr.2002.63.538 Publication
Researcher Affiliations
- Department of Veterinary Clinical Medicine, University of Illinois, Urbana 61802, USA.
MeSH Terms
- Animals
- Blood Gas Analysis / veterinary
- Blood Pressure / drug effects
- Carboxylic Acids / toxicity
- Cardiac Output / drug effects
- Cardiovascular Diseases / blood
- Cardiovascular Diseases / chemically induced
- Cardiovascular Diseases / physiopathology
- Cardiovascular Diseases / veterinary
- Encephalomalacia / chemically induced
- Encephalomalacia / physiopathology
- Enzyme Inhibitors / toxicity
- Fumonisins
- Heart Rate / drug effects
- Horse Diseases / blood
- Horse Diseases / chemically induced
- Horse Diseases / physiopathology
- Horses
- Injections, Intravenous / veterinary
- Mycotoxins / toxicity
- Myocardium / metabolism
- Random Allocation
- Sphingolipids / blood
- Troponin I / blood
Citations
This article has been cited 9 times.- Schrenk D, Bignami M, Bodin L, Chipman JK, Del Mazo J, Grasl-Kraupp B, Hogstrand C, Leblanc JC, Nielsen E, Ntzani E, Petersen A, Sand S, Schwerdtle T, Vleminckx C, Wallace H, Daenicke S, Nebbia CS, Oswald IP, Rovesti E, Steinkellner H, Hoogenboom LR. Assessment of information as regards the toxicity of fumonisins for pigs, poultry and horses. EFSA J 2022 Aug;20(8):e07534.
- Durham AE. Association between forage mycotoxins and liver disease in horses. J Vet Intern Med 2022 Jul;36(4):1502-1507.
- Perera D, Savocchia S, Prenzler PD, Thomson PC, Steel CC. Occurrence of fumonisin-producing black aspergilli in Australian wine grapes: effects of temperature and water activity on fumonisin production by A. niger and A. welwitschiae. Mycotoxin Res 2021 Nov;37(4):327-339.
- Chen J, Wen J, Tang Y, Shi J, Mu G, Yan R, Cai J, Long M. Research Progress on Fumonisin B1 Contamination and Toxicity: A Review. Molecules 2021 Aug 29;26(17).
- Knutsen HK, Alexander J, Barregård L, Bignami M, Brüschweiler B, Ceccatelli S, Cottrill B, Dinovi M, Edler L, Grasl-Kraupp B, Hogstrand C, Hoogenboom LR, Nebbia CS, Petersen A, Rose M, Roudot AC, Schwerdtle T, Vleminckx C, Vollmer G, Wallace H, Dall'Asta C, Eriksen GS, Taranu I, Altieri A, Roldán-Torres R, Oswald IP. Risks for animal health related to the presence of fumonisins, their modified forms and hidden forms in feed. EFSA J 2018 May;16(5):e05242.
- Bertero A, Moretti A, Spicer LJ, Caloni F. Fusarium Molds and Mycotoxins: Potential Species-Specific Effects. Toxins (Basel) 2018 Jun 15;10(6).
- Pierron A, Alassane-Kpembi I, Oswald IP. Impact of two mycotoxins deoxynivalenol and fumonisin on pig intestinal health. Porcine Health Manag 2016;2:21.
- Reisinger N, Dohnal I, Nagl V, Schaumberger S, Schatzmayr G, Mayer E. Fumonisin B₁ (FB₁) Induces Lamellar Separation and Alters Sphingolipid Metabolism of In Vitro Cultured Hoof Explants. Toxins (Basel) 2016 Mar 24;8(4):89.
- Foreman JH, Tennent-Brown BS, Oyama MA, Sisson DD. Plasma Cardiac Troponin-I Concentration in Normal Horses and in Horses with Cardiac Abnormalities. Animals (Basel) 2025 Jan 3;15(1).
Use Nutrition Calculator
Check if your horse's diet meets their nutrition requirements with our easy-to-use tool Check your horse's diet with our easy-to-use tool
Talk to a Nutritionist
Discuss your horse's feeding plan with our experts over a free phone consultation Discuss your horse's diet over a phone consultation
Submit Diet Evaluation
Get a customized feeding plan for your horse formulated by our equine nutritionists Get a custom feeding plan formulated by our nutritionists
